Antipsychotic prescribing in nursing homes

BMJ (Online)

Volumn 344, Issue 7848, 2012, Pages

  McCleery, Jenny ^a   Fox, Robin ^b  

^a OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b Health Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE;

AGGRESSION; AGITATION; BEHAVIOR DISORDER; COMMUNITY CARE; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; INSTITUTIONAL CARE; MEDICAL PRACTICE; MENTAL DISEASE; MORTALITY; NURSING HOME; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RESOURCE ALLOCATION; RISK ASSESSMENT; RISK REDUCTION; SYMPTOM; FEMALE; HUMAN; MALE; NOTE; STATISTICS;

ANTIPSYCHOTIC AGENTS; DEMENTIA; FEMALE; HUMANS; MALE; MORTALITY; NURSING HOMES;

EID: 84858376589     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e1093     Document Type: Editorial

References (12)

1. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43. (Pubitemid 41464695)
2. Food and Drug Administration. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. 2005. www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171. htm.
3. European Medicines Agency. Questions and answers on the review of the use of conventional antipsychotic medicines in elderly patients with dementia. 2008. www.ema.europa.eu/docs/en-GB/document-library/Other/2010/01/WC500054058. pdf.
4. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012;344:e977.
5. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harms. Nat Rev Neurosci 2006;7:492-500. (Pubitemid 44012289)
6. Maher A, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306:1359-69.
7. Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 2011;10:35-43.
8. Azermai M, Petrovic M, Elseviers MM, Bourgeois J, Van Bortel LM, Vander Stichele RH. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Res Rev 2012;11:78-86.
9. National Institute for Health and Clinical Excellence. Dementia: supporting people with dementia and their carers in health and social care. 2006. http://guidance.nice.org.uk/CG42.
10. Shah SM, Carey IM, Harris T, Dewilde S, Cook DG. Antipsychotic prescribing to older people living in care homes and the community in England and Wales. Int J Geriatr Psychiatry 2011;26:423-34.
11. Wood-Mitchell A, James IA, Waterworth A, Swann A, Ballard C. Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study. Age Ageing 2008;37:547-52.
12. Treloar A, Crugel M, Prasanna A, Solomons L, Fox C, Paton C, et al. Ethical dilemmas: should antipsychotics ever be prescribed for people with dementia? Br J Psychiatry 2010;197:88-90.